Sansure Biotech (SHSE:688289) ROCE %: 2.76% (As of Mar. 2026)

What is Sansure Biotech ROCE %?

Sansure Biotech SHSE:688289 -2.04% 62 ROCE % is 2.76% as of Mar. 2026. GuruFocus rates SHSE:688289 with a GF Score™ of 62/100 and a GF Value™ of ¥20.52 (Possible Value Trap). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sansure Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was 2.76%.

Sansure Biotech (SHSE:688289) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sansure Biotech ROCE % Related Terms

Sansure Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Sansure Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sansure Biotech ROCE % Chart

Sansure Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

46.75

33.05

5.46

3.63

2.46

Sansure Biotech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															5.19	3.66	0.74	0.09	2.76

62GF Score

Sansure Biotech Inc SHSE:688289

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sansure Biotech ROCE % Calculation

Sansure Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	199.209	/	( ( (8603.796 - 754.803)	+	(9526.68 - 1206.017) )	/ 2 )
	=	199.209	/	( (7848.993	+	8320.663)	/ 2 )
	=	199.209	/	8084.828
	=	2.46 %

Sansure Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	230.836	/	( ( (9526.68 - 1206.017)	+	(9606.771 - 1210.639) )	/ 2 )
	=	230.836	/	( ( 8320.663	+	8396.132 )	/ 2 )
	=	230.836	/	8358.3975
	=	2.76 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 2.76% mean?

Sansure Biotech (SHSE:688289) has a ROCE % of 2.76% as of Mar. 2026.

Is Sansure Biotech's ROCE % too high?

Sansure Biotech's current ROCE % is 2.76%. The Medical Devices & Instruments industry median ROCE % is 2.20. Sansure Biotech's value of 2.76% is 25.5% above this industry median. Overall, Sansure Biotech has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Sansure Biotech's ROCE % compare to ISRG and BDX?

Sansure Biotech's ROCE % of 2.76% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. Sansure Biotech's value of 2.76% is 25.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sansure Biotech's current ROCE % of 2.76% is 25.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sansure Biotech's current ROCE % is 2.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sansure Biotech stock overvalued right now?

Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Possible Value Trap. The stock's GF Value™ is ¥20.52, compared to a current price of ¥14.40 — trading 29.8% below its estimated fair value. The current ROCE % is 2.76% and 25.5% above the Medical Devices & Instruments industry median of 2.20. Sansure Biotech's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current ROCE % is 2.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sansure Biotech (SHSE:688289) Overvalued in 2026?

Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued. The current stock price of ¥14.40 is trading 29.8% below its estimated GF Value™ of ¥20.52. GuruFocus considers Sansure Biotech to be Possible Value Trap.

Key valuation signals for SHSE:688289:

ROCE %: 2.76%
GF Value™: ¥20.52 vs. price of ¥14.40 (29.8% below fair value)
GF Score™: 62/100 with 7 warning signs
Industry Position: 25.5% above the Medical Devices & Instruments median

No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sansure Biotech Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies SZSE:300171 SHSE:688050 SHSE:688277 SZSE:300595 SZSE:301580 SZSE:002950 SZSE:300358 SZSE:301101 SZSE:002382 SHSE:688151 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543

Address No. 680, Lusong Road, Changsha High-tech Industrial Development Zone, Hunan Province, Changsha, CHN, 410205

Website http://www.sansure.com.cn

Sansure Biotech Inc is engaged in the Research, development, production, and sales of diagnostic reagents and instruments.

62GF Score

Get the complete analysis for SHSE:688289

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.40

Price

¥20.52

GF Value

View SHSE:688289 Analysis

See ROCE % data for all stocks →